Edgar Filing: Sage Therapeutics, Inc. - Form 4

Sage Therapeuti Form 4 April 02, 2015	cs, Inc.										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION								OMB APPROVAL			
Washington, D.C. 20549							OMB Number:	3235-0287			
Check this bo if no longer subject to		STATEMENT OF CHANGES IN BENEFICIAL OWNERSH						NERSHIP OF	Expires:	January 31, 2005	
Section 16. SECURITIES Form 4 or							Estimated a burden hour response				
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type Resp	onses)										
PAUL STEVEN M Symbol				r Name and Ticker or Trading herapeutics, Inc. [SAGE]				5. Relationship of Reporting Person(s) to Issuer			
								(Check all applicable)			
(Last)	Last) (First) (Middle) 3. Date of				ransaction						
			(Month/E 04/01/2	/Day/Year) /2015				Director 10% Owner Officer (give title Other (specify below)			
				endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check			
								Applicable Line)			
CAMBRIDGE, MA 02142								_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tabl	le I - Non-D	Derivative S	Securi	ties Acq	uired, Disposed of,	, or Beneficiall	ly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)			3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D)	Price \$	Transaction(s) (Instr. 3 and 4)			
Common 04 Stock	/01/2015			S	20,000	D	48.51 (<u>1)</u>	783,650	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Sage Therapeutics, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D)	Expiration Date (Month/Day/Year)		7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(Instr. 3, 4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Relationships

Director

10% Owner Officer Other

Reporting Owners

PAUL STEVEN M

Reporting Owner Name / Address

C/O SAGE THERAPEUTICS, INC.

215 FIRST STREET CAMBRIDGE, MA 02142 Signatures

/s/ Laurie Burlingame, as Attorney-in-Fact for Steven M. Paul

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was executed in multiple trades at prices ranging from \$48.50 USD to \$48.80 USD. The price reported above reflects the weighted average sale price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Date

04/01/2015